• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • HIV/AIDS

    Exclusive: USAID says no Kenya HIV medication deal

    USAID says a large shipment of HIV medication stuck in diplomatic limbo has not yet been released — despite remarks made by Kenyan Health Cabinet Secretary Mutahi Kagwe on Wednesday.

    By Sara Jerving // 22 April 2021
    Empty boxes of HIV medicine are seen in a garbage bin at a treatment center in Nairobi, Kenya. Photo by: Baz Ratner / Reuters

    A spokesperson for the U.S. Agency for International Development told Devex on Thursday that a large shipment of HIV medication stuck in diplomatic limbo has not yet been released — despite remarks made Wednesday by Mutahi Kagwe, Kenyan Cabinet secretary for health.

    The Kenyan government has been in a stalemate with USAID over a large batch of antiretroviral treatment and other donated health supplies that have been stranded at the Port of Mombasa since mid-January. The issue under dispute is which entity will distribute the drugs: Kenya Medical Supplies Authority or the U.S.-based private company Chemonics.

    Sign up for Devex CheckUp

    The must-read newsletter for exclusive global health news and insider insights.

    Because of this, HIV treatment for the 1.2 million HIV-positive people living in Kenya is running “dangerously low,” as Devex previously reported. Treatment for children and lab reagents for testing HIV in babies are already out of stock. Most counties lack tuberculosis tests as well.

    On Wednesday, Kagwe told the Kenyan National Assembly’s Health Committee: “The commodities have already been released to the country. That issue has been resolved.”

    He added that “the U.S. government actually agreed that we use the system that we have been using in the past for distribution.”

    But according to a USAID spokesperson, the medication and medical supplies “that were stuck at Mombasa Port remain in USAID’s possession until our deliberations conclude.”

    While Kagwe’s remarks suggested the shipment donated by USAID was released from the port, the U.S. agency clarified the medications that were released this week are from another donor — the Global Fund to Fight AIDS, Tuberculosis and Malaria — and not from USAID. The Kenyan government made an arrangement with the Global Fund to support the country with drugs for the next three months. This arrangement is seen by civil society organizations as a Band-Aid measure that doesn’t lead to a return to multimonth dispensing of the drugs.

    As the largest contributor to the Global Fund, the United States is also a donor of the medication released this week, but it is not the same supply of drugs under dispute with USAID.

    Supplies run low as Kenya and US standoff over HIV drugs

    A standoff between the Kenyan government and USAID has resulted in much-needed HIV medication being stuck at a port in Mombasa while some Kenyans are resorting to skipping doses.

    USAID and Kenya Medical Supplies Authority had a five-year contract that ended in 2020. USAID then asked the Global Health Supply Chain - Procurement and Supply Management — implemented by Chemonics and a consortium of partners — to procure HIV, malaria, and family planning commodities for Kenya instead of KEMSA. Last year, KEMSA faced allegations of corruption and mismanagement of COVID-19 funds. Kagwe said USAID decided to not use the state corporation for distribution of the HIV drugs because it did not trust KEMSA.

    In response, the Kenyan government initially demanded 90 million Kenyan shillings ($829,000) in importation taxes on the drugs, saying it wasn’t a tax-exempt government-to-government donation, but has since waived these. According to civil society organizations, though, the government is still insisting the drugs be delivered through its own system and not USAID’s private partner, creating the ongoing impasse.

    Kagwe said the Kenyan government was actively working to address USAID’s “lack of trust” in KEMSA by “making changes in the organization that we are sure are going to satisfy the U.S. government and USAID.”

    Update, April 22, 2021: This article has been updated with new details and quotes from Mutahi Kagwe.

    • Global Health
    • Private Sector
    • KEMSA
    • USAID
    • Kenya
    • United States
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Sara Jerving

      Sara Jervingsarajerving

      Sara Jerving is a Senior Reporter at Devex, where she covers global health. Her work has appeared in The New York Times, the Los Angeles Times, The Wall Street Journal, VICE News, and Bloomberg News among others. Sara holds a master's degree from Columbia University Graduate School of Journalism where she was a Lorana Sullivan fellow. She was a finalist for One World Media's Digital Media Award in 2021; a finalist for the Livingston Award for Young Journalists in 2018; and she was part of a VICE News Tonight on HBO team that received an Emmy nomination in 2018. She received the Philip Greer Memorial Award from Columbia University Graduate School of Journalism in 2014.

    Search for articles

    Related Stories

    Global HealthFrustration mounts as Uganda faces HIV treatment shortages

    Frustration mounts as Uganda faces HIV treatment shortages

    Devex CheckUpDevex CheckUp: USAID cuts threaten global health research

    Devex CheckUp: USAID cuts threaten global health research

    The Future of US AidWho’s still standing? USAID’s new top 15 implementers

    Who’s still standing? USAID’s new top 15 implementers

    Most Read

    • 1
      Opinion: AI-powered technologies can transform access to health care
    • 2
      Exclusive: A first look at the Trump administration's UNGA priorities
    • 3
      WHO anticipates losing some 600 staff in Geneva
    • 4
      Opinion: Resilient Futures — a world where young people can thrive
    • 5
      AIIB turns 10: Is there trouble ahead for the China-backed bank?
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement